Crown Bioscience Inc.
CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, is proud to announce the award of its Patient-Derived Xenograft (PDX) grant program to doctors Fabrice Lavial, Christophe Caux and Bertrand Dubois from the Cancer Research Center of Lyon (CRCL).
The grant program was established to support oncology researchers pursuing scientific advancements in cancer using PDX technology. Following an extensive review, CrownBio's Scientific Steering Committee selected Dr. Lavial and his colleagues at the CRCL due to their project's potential to create breakthroughs in preclinical oncology strategies. Their research combines PDX and iPS cell technologies to create patient-specific, humanized models. These unique models will help scientists assess the efficacy of novel immuno-oncology therapeutics, reveal new information about the immune system's involvement in cancer and identify resistance mechanisms to current immunotherapies.
"CrownBio launched our PDX grant program with the goal of accelerating the pace of preclinical innovation to improve clinical predictions with sound science," Dr. Henry Li, SVP Global Scientific Research and Innovation commented. "The CRCL's iPS PDX models exemplify this goal by providing researchers with novel models they can use to formulate new strategies that harness immune cells to treat cancer."
"We believe the cutting-edge research models that will be developed at the CRCL will deepen researchers' understanding of the immune system's role in cancer genesis and progression," said Michael Prosser, VP Corporate Development and Strategy. "Using this knowledge, researchers can make better decisions in drug development and design more effective immunotherapeutics, so we are proud and excited to make CRCL's concept a reality."
About Crown Bioscience
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Abeona Therapeutics Inc.21.5.2019 14:03:09 CEST | Pressemeddelelse
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
Invivoscribe, Inc.21.5.2019 12:02:33 CEST | Pressemeddelelse
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
GridGain Systems21.5.2019 09:02:54 CEST | Pressemeddelelse
GridGain Joins Cloud Native Computing Foundation
IMImobile21.5.2019 09:02:54 CEST | Pressemeddelelse
Telia Norway signs partner agreement with IMImobile for Enterprise cPaaS offering
Worksoft20.5.2019 17:56:04 CEST | Pressemeddelelse
Deutsche Telecom to Showcase How Intelligent Automation is Driving Quality and Program Efficiencies for ERP Transformation
Merus N.V.20.5.2019 14:41:11 CEST | Pressemeddelelse
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum